Home
Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

Today’s Highlights July 8, 2019

Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in Hemophilia Patients
Sangamo Therapeutics (SGMO) and Pfizer (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
,
July 8, 2019

Other Articles